Tris Pharma

What Tris Pharma does

Tris Pharma is a privately held, commercial-stage biopharmaceutical company founded in 2000 by Ketan Mehta and headquartered in Monmouth Junction, New Jersey. The company develops and commercializes specialty pharmaceuticals focused on central nervous system disorders, with a mature ADHD franchise (Dyanavel XR, Quillivant XR, QuilliChew ER, and Onyda XR — the only liquid non-stimulant ADHD medication) and a growing clinical pipeline spanning acute and chronic pain (cebranopadol, a first-in-class dual NOP/MOP receptor agonist with positive Phase 3 results), sleep disorders (TRN-257, a low-sodium, once-nightly oxybate with FDA Orphan Drug Designation), opioid use disorder, and other CNS indications.

The company's competitive foundation rests on two proprietary drug delivery platforms: LiquiXR, a particle-based technology that combines ionic chemistry with controlled-release science to produce extended-release oral suspensions, chewable tablets, and orally disintegrating tablets; and RaftWorks, an interpenetrating polymer network technology that creates an in-situ floating raft in the upper GI tract for sustained drug absorption. These platforms have generated 9+ FDA-approved NDAs and power more than a dozen approved or investigational therapies. Additional supporting technologies include Lipisol, maxsol, and eXsol for transforming medicines into patient-friendly oral dosage forms.

Tris generates revenue through three primary streams: branded pharmaceutical sales (ADHD products marketed directly to healthcare providers and distributed through US pharmacies and wholesalers), generic pharmaceutical sales (through wholly owned subsidiary Cranbury Pharmaceuticals, including the first generic version of Emflaza for Duchenne Muscular Dystrophy), and technology licensing/royalty income (out-licensing LiquiXR, RaftWorks, and finished products to regional partners in 33+ countries, including Kye Pharmaceuticals in Canada, Neuraxpharm across 40+ European countries, Pediatrix Therapeutics in China, and Perrigo for select US products). The company is expanding beyond small-molecule pharmaceuticals into digital health through an AI-enhanced ADHD diagnostic platform licensed from Braingaze.

Name

Tris Pharma

Legal name

Tris Pharma, Inc.

Website

https://trispharma.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Tris Pharma is a private biopharmaceutical company developing and commercializing specialty CNS pharmaceuticals for ADHD, pain, addiction, and sleep disorders, anchored on proprietary LiquiXR and RaftWorks drug-delivery platforms and serving patients and healthcare providers across 33+ countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals - CNS Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Specialty pharmaceuticals
• CNS therapeutics
• ADHD medications
• Drug delivery technology
• Extended-release formulations

Headquarters

HQ city

Monmouth Junction

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Others

Revenue model

1. Branded Pharmaceutical Sales: Revenue from proprietary branded pharmaceutical products including ADHD medications (Dyanavel XR, Quillivant XR, QuilliChew ER, Onyda XR) marketed directly to healthcare providers and distributed through pharmacies.
2. Generic Pharmaceuticals: Revenue from generic pharmaceutical products through Cranbury Pharmaceuticals subsidiary, including first generic version of Emflaza for Duchenne Muscular Dystrophy and other generic medications.
3. Technology Licensing: Revenue from licensing proprietary drug delivery technologies (LiquiXR®, RaftWorks™) to pharmaceutical partners worldwide for development and commercialization of their products.
4. International Partnerships: Revenue from out-licensing approved products and pipeline candidates to international partners for development and commercialization in ex-US territories.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

Tris Pharma develops, manufactures, and commercializes branded and generic specialty pharmaceuticals for central nervous system (CNS) disorders, with a commercial franchise in ADHD (Dyanavel XR, Quillivant XR, QuilliChew ER, Onyda XR) and a pipeline spanning pain (cebranopadol), sleep disorders (TRN-257), and other CNS indications. The company leverages proprietary drug delivery technology platforms (LiquiXR®, RaftWorks™, Lipisol™, maxsol™, eXsol™) to produce differentiated patient-friendly dosage forms including extended-release oral suspensions, chewable tablets, and orally disintegrating tablets. Tris also generates revenue through out-licensing its drug delivery technologies and products to international partners.

Product overview

Tris Pharma is a biopharmaceutical company with a diversified portfolio of ADHD medications and a pipeline spanning pain, addiction, and CNS disorders. The core ADHD portfolio includes four FDA-approved products: Dyanavel XR (amphetamine, oral suspension and tablets), Quillivant XR (methylphenidate oral suspension), QuilliChew ER (methylphenidate chewable tablets), and ONYDA XR (clonidine oral suspension - the only liquid non-stimulant ADHD option). The pipeline includes TRN-257 (low-sodium oxybate for narcolepsy/idiopathic hypersomnia, NDA accepted by FDA), cebranopadol (first-in-class dual-NMR agonist for pain, Phase 3 completed for acute pain), TRN-213 (for spasticity, Phase 2), TRN-218 (pediatric ADHD, Phase 2), and TRN-261 (peptide analgesic). The company also operates a digital health business developing an AI-enhanced ADHD diagnostic platform. Technology platforms include LiquiXR (particle-based extended-release technology powering over a dozen therapies) and RaftWorks (controlled absorption technology). The generics business is managed through subsidiary Cranbury Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Brands

• LiquiXR: Proprietary drug delivery technology platform enabling extended-release formulations in liquid, chewable tablet, film strip and orally disintegrating tablet dosage forms.
• RaftWorks
• Cranbury Pharmaceuticals
• NextWave Pharmaceuticals

Products and services

• DYANAVEL XR (amphetamine) Once-daily extended-release amphetamine ADHD medication available as oral suspension and chewable/swallowable tablets for patients 6 years and older. Uses LiquiXR® technology for extended-release delivery and can be chewed or swallowed whole.
• Quillivant XR (methylphenidate) Extended-release methylphenidate oral suspension for ADHD treatment, using LiquiXR® technology for once-daily dosing. Marketed by NextWave Pharmaceuticals, a wholly owned subsidiary of Tris Pharma.
• QuilliChew ER (methylphenidate) First FDA-approved extended-release chewable methylphenidate tablet for ADHD, using LiquiXR® technology for flexible dosing. Marketed by NextWave Pharmaceuticals, a wholly owned subsidiary of Tris Pharma.
• ONYDA XR (clonidine hydrochloride) First and only FDA-approved liquid non-stimulant ADHD medication (extended-release oral suspension). Approved as monotherapy or adjunctive therapy to stimulant medications for patients 6 years and older. Uses LiquiXR® technology.
• Cebranopadol First-in-class dual NOP/MOP receptor agonist (dual-NMR) for moderate-to-severe acute pain, chronic pain, neuropathic pain, and opioid use disorder. Phase 3 completed for acute pain (ALLEVIATE-1 and ALLEVIATE-2 trials met primary endpoints). Fast Track Designation granted for chronic low back pain. Studied in over 2,200 patients across 33 clinical trials.
• TRN-257 (Oxybate Extended-Release) Investigational once-nightly, low-sodium oxybate product for treating narcolepsy and idiopathic hypersomnia. Uses RaftWorks™ and LiquiXR® platforms. Contains 80mg sodium per 9g dose (lowest among oxybate products in development). FDA NDA accepted December 2025; Orphan Drug Designation granted June 2026.
• TRN-261 First-in-class peptide molecule analgesic in development for multiple acute and chronic pain indications. Extensively studied clinically in non-pain indications with strong potential for effective pain relief.
• TRN-213 Optimized formulation for spasticity treatment associated with multiple sclerosis and other diseases like cerebral palsy. Designed as extended-release treatment option for more consistent daily efficacy, higher adherence, and reduced side effects. Phase 2 stage.
• TRN-218 Once-daily oral suspension extended-release ADHD treatment under investigation for pediatric patients with ADHD. Designed with profile expected to be favorable for autism spectrum disorder (ASD) patients. Phase 2 stage.
• Cranbury Pharmaceuticals Generics Portfolio Subsidiary handling Tris Pharma's generics portfolio and pipeline, including the first generic version of Emflaza (deflazacort) oral suspension for Duchenne Muscular Dystrophy. Operates as Cranbury Pharmaceuticals, debuted June 2024.

Quantifiable outcome

• Phase 3 ALLEVIATE-1 (abdominoplasty): LS mean difference 59.2 in pain score AUC vs placebo (p<0.001)
• +6 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered major and core.

• Perigon Pharmacy 360majorChannel Partner/ Reseller/ Distributor · 30 October 2023Partnership to enhance accessibility, affordability and adherence for Dyanavel XR tablets via digital pharmacy services, providing patients with convenient prescription management and delivery options.
• CenExel Clinical ResearchmajorImplementation/ SI/ Consulting Partner · 7 December 2022CenExel conducted ALLEVIATE-2 Phase 3 clinical trial for cebranopadol at multiple U.S. research sites, with Dr. Todd Bertoch serving as Chief Medical Officer and Principal Investigator.
• Pediatrix TherapeuticscoreChannel Partner/ Reseller/ Distributor · 1 December 2022Expansion of partnership to commercialize Tris' FDA-approved ADHD medicines and investigational ADHD therapy in China. Original partnership established December 2020 and expanded in December 2022.
• Park TherapeuticscoreStrategic or Co-development Partner · 29 April 2021Acquisition of Park Therapeutics including first-in-class, Phase III-ready new chemical entity for pain, expanding Tris' pain pipeline. This acquisition brought cebranopadol into Tris' development portfolio.
• Neuraxpharm GroupcoreChannel Partner/ Reseller/ Distributor · 8 December 2020Partnership to commercialize Tris' Quillivant XR and Quillichew ER in 40+ European countries. Neuraxpharm holds rights to develop and commercialize approved ADHD products across major European markets.
• Kye PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 9 July 2020Exclusive license agreement to commercialize Tris ADHD products in Canada. Kye Pharmaceuticals serves as Tris Pharma's first ex-U.S. partner for approved ADHD portfolio, bringing Dyanavel XR tablets to Canadian patients in 2026.
• Perrigo CompanymajorChannel Partner/ Reseller/ DistributorLong-standing commercial partnership since 2012 for various pharmaceutical products.
• BraingazecoreStrategic or Co-development PartnerLicensed rights to develop and commercialize Braingaze's first-in-class AI-enhanced digital ADHD diagnostic platform in the United States and Canada, expanding Tris' digital health offerings.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Jazz Pharmaceuticals: Direct TRN-257 competitor through Xywav (oxybate) franchise for narcolepsy and idiopathic hypersomnia. Comparable CNS specialty pharma with strong orphan drug positioning and ADHD-adjacent CNS portfolio.
• Supernus Pharmaceuticals: Specialty CNS pharma with overlapping ADHD portfolio (Qelbree, Adzenys) and adjacent CNS pipeline. Closely comparable business model of branded specialty pharma with proprietary delivery technologies and CNS focus.
• BioDelivery Sciences International: Specialty pharma with pain franchise (Belbuca, buprenorphine) and proprietary drug delivery platforms. Comparable model of branded specialty pharma using differentiated formulation to compete in CNS/pain markets.
• Avadel Pharmaceuticals: Direct TRN-257 competitor with FT218 (Lumryz), an extended-release once-nightly sodium oxybate for narcolepsy. Highly comparable in patient-friendly reformulation strategy targeting same oxybate market.
• Camber Pharmaceuticals: Generic pharmaceutical company directly comparable to Tris's Cranbury Pharmaceuticals subsidiary. Similar generics portfolio strategy and CNS/general medicine focus.
• Collegium Pharmaceutical: CNS specialty pharma with pain focus (Xtampza, Belbuca) and ADHD presence via Ironshore acquisition ( Jornay PM, Adhansia XR). Comparable commercial-stage specialty CNS business model and patient-friendly formulation strategy.
• Aytu BioPharma: Acquired Neos Therapeutics' ADHD portfolio (Adzenys, Cotempla) — directly competes with Tris's Quillivant XR and Dyanavel XR in the branded stimulant ADHD market. Similar mid-sized specialty CNS profile.

Broad incumbents

• Lundbeck: Large established CNS specialty pharma (Onfi, Sabril, Rexulti) with portfolio overlap in CNS disorders including ADHD-adjacent and sleep. Broader portfolio than Tris but similar patient-focused CNS specialty approach.
• Mallinckrodt Pharmaceuticals: Specialty pharma with overlapping CNS portfolio (ADHD, pain) and generic specialty pharmaceuticals business. Notable as multiple Tris executives (Manesh Naidu, Jim Potenziano) previously worked there.

Emerging players

• KemPharm: Specialty CNS pharma developing prodrug ADHD stimulants (Azstarys) with proprietary delivery technology. Direct competitive overlap in ADHD with smaller commercial footprint than Tris.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• Xx.com/TrisPharmaCorp
• Facebookfacebook.com/trispharmacorporate
• LinkedInlinkedin.com/company/trispharma
• Instagraminstagram.com/trispharmacorporate

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tris Pharma